Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2929)	6/15/2010 11:17:18 AM
From: mlkr	Respond to of 3722

ATRC went up from 1.50s in april 10 to 6.43 today.. NEW YORK (TheStreet) -- AtriCure (ATRC) was one of several stocks trading near $5 poised to move on above-average volume Tuesday after the company's heart device received regulatory clearance in the U.S. AtriCure said the Food and Drug Administration gave clearance to its AtriClip system, which is designed to be implanted from the outside of the heart, avoiding contact with circulating blood and eliminating blood flow between the left atrial appendage and the atria. AtriCure said the initial launch of the AtriClip system in the U.S. is expected to begin later this month with full commercial release planned during the third quarter of 2010. AtriCure shares jumped by 92 cents, or 17.6%, to $6.15 in the premarket session. The 50-day average daily volume for AtriCure is 27,000, according to the Nasdaq.

To: Jibacoa who wrote (2929)	6/15/2010 11:34:40 AM
From: mlkr	Read Replies (2) \| Respond to of 3722

ATRC Amazing : 6.43 now! It was 1.50s around april 10; now better than Boston Scientific? Bernard would you do a technical/fundamental analysis on BSX and show bth BSX and ATRC on a comparative chart? tia mlkr NEW YORK (TheStreet) -- AtriCure (ATRC) was one of several stocks trading near $5 poised to move on above-average volume Tuesday after the company's heart device received regulatory clearance in the U.S. AtriCure said the Food and Drug Administration gave clearance to its AtriClip system, which is designed to be implanted from the outside of the heart, avoiding contact with circulating blood and eliminating blood flow between the left atrial appendage and the atria. AtriCure said the initial launch of the AtriClip system in the U.S. is expected to begin later this month with full commercial release planned during the third quarter of 2010. AtriCure shares jumped by 92 cents, or 17.6%, to $6.15 in the premarket session. The 50-day average daily volume for AtriCure is 27,000, according to the Nasdaq.